BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

4.3050-0.2950 (-6.41%)

At close: 4:00PM EDT

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Continuation Wedge (Bullish)

View all chart patterns

Performance Outlook

Previous Close	4.6000
Open	4.5500
Bid	4.3000 x 3200
Ask	4.3600 x 1300
Day's Range	4.2500 - 4.5541
52 Week Range	1.3800 - 6.2900
Volume	7,110,792
Avg. Volume	7,707,306

Market Cap	760.117M
Beta (5Y Monthly)	2.75
PE Ratio (TTM)	N/A
EPS (TTM)	-0.8350
Earnings Date	Nov 04, 2020 - Nov 09, 2020
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	8.50

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

Motley Fool
Here's Why BioCryst Pharmaceuticals Jumped Higher Today
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) are up 14.5% at 1:16 p.m. after the biotech's new CFO, Anthony Doyle, purchased 54,000 shares of the company at $4.08 per share. As they say, there are many reasons an executive might feel the need to sell shares, but there's only one reason to buy: Doyle clearly thinks shares are undervalued at this point. BioCryst's valuation has increased dramatically as investors have rushed in ahead of anticipated approvals in the U.S. and Japan for its hereditary angioedema treatment, Orladeyo.
Zacks
Do Options Traders Know Something About BioCryst Pharmaceuticals (BCRX) Stock We Don't?
Investors need to pay close attention to BioCryst Pharmaceuticals (BCRX) stock based on the movements in the options market lately.
- Implied Volatility Surging for American Eagle (AEO) Stock Options
  Zacks
- Are Options Traders Betting on a Big Move in 1Life Healthcare (ONEM) Stock?
  Zacks
Zacks
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Misses Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of 14.29% and -9.43%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?